This article is more than 5 years old. Information may no longer be current.

VIDEO: Veltassa demonstrates lower potassium levels in patients with hyperkalemia

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AUSTIN, Texas — At the National Kidney Foundation Spring Clinical Meetings, Matthew R. Weir, MD, spoke about results of a study that measured the efficacy and safety of Veltassa for patients with hyperkalemia.

The results presented in a poster here were from a pooled analysis of 653 patients from the OPAL-HK, AMETHYST-DN and TOURMALINE phase 3 clinical studies. Overall, 98% of the patients had hypertension and 93% of patients were taking renin-angiotensin-aldosterone system (RAAS)-inhibitor therapy.

Weir said results demonstrate the utility of the new approach to control hyperkalemia, as Veltassa (patiromer, Relypsa Inc.) consistently reduced potassium levels in the patients studied, including patients on RAAS-inhibitor therapy.